Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
Thrombosis & Haemostasis Journal (TH Open) has recently shared a promising data on Emicizumab efficacy on X:
”Implementing an Assay to detect Anti-drug Antibody against Emicizumab: Experience from One Center in France. Auditeau et al. evaluated the effectiveness of a modified bridging ELISA in detecting anti-drug antibodies.”
Read the full article here.
A bispecific antibody mimicking factor VIII, is approved for prophylaxis in hemophilia A — but what could possibly go wrong with a drug designed to work perfectly?
Although rare, anti-drug antibodies (ADA) can reduce its efficacy,using data from One center in France.
The study by Claire Auditeau et al. aimed to investigate potential causes behind the loss of Emicizumab efficacy.
Using a modified bridging ELISA, ADA was detected in two patients—one newly identified with a neutralizing ADA that blocked Emicizumab’s binding to factors IX and X.
In ADA-negative cases, bispecific antibody’s levels improved following adherence adjustments.
The findings suggest that the assay may help distinguish ADA-related loss of efficacy from non-immunologic causes in patients with unexplained bleeding.
Updates on thrombosis and hemostasis field advancements featured in Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis